On May 22, 2017 the European Medicines Agency’s (EMA) management board endorsed the start of the official countdown for the launch of the improved EudraVigilance database system for collecting and monitoring suspected adverse reactions.

Read more

The EMA recently announced that they will be delaying the roll-out of the new ISO IDMP standard within Europe until after the completion of the formal Brexit processes. This means that no EU Implementation Guidelines (EU IGs) will be published in 2018, and there will be no need to start submitting product data in the new format in 2019.

It may have caused a disturbance in the industry, but whether you were skeptical about the original implementation deadlines or not, one thing remains - IDMP will still happen, with or without Brexit!

So how should you react? Is this a time to relax and enjoy some spare cycles in your day? Or, is this your opportunity to be proactive and push forward with your plans knowing that IDMP is not only about regulatory standards, but also a significant opportunity for your business to improve its own internal data handling processes?

Read more

From the beginning of next year, Health Canada will only accept submissions for certain regulatory procedures in the electronic common technical document (eCTD) format. As of that date, Health Canada says that sponsors must use eCTD format for all new drug submissions (NDS) and abbreviated new drug submissions (ANDS), as well as supplements to both submission types. On 24th of April 2017, Health Canada officially confirmed the deadline for eCTD submissions - to read the official announcement from Health Canada, click here.

Read more

With eRA 2017 behind us and the craziness of the last few months of back-to-back organization now over, it's time to take a step back and look at what we learned at this year's eRA event. This year was my first time at eRA. From the latest IDMP updates to the best tapas dish of the meal, and everything in between, there were great discussions all around. For the conversation alone, I must say that it was a couple of days well invested. With 40 keynote and breakout sessions taking place over the course of the two days, there was also plenty to see and learn.

Read more

Come May 5, 2018, all Drug Master File (DMF) submissions will need to be filed electronically with FDA in an eCTD format, or they will be rejected. This upcoming regulation is expected to promote efficiency of the DMF review process, but are companies ready to comply? Learn more about the new regulation and how to navigate the transition in order to remain compliant.

Read more

South America is still taking its first tentative steps towards the standardization of submission dossier formats for registered medicinal products. Most countries within the region have their own local format and some allow information to be submitted electronically on their local portals.

Read more

Updated pharmacovigilance legislation within the EU will bring about significant changes to the requirements surrounding reporting of suspected adverse reactions and non-serious cases. To support these changes, the European Medicines Agency (EMA) is launching a new EudraVigilance system with enhanced functionality. In November 2017 the reporting of non-serious cases will become mandatory.

Read more

The changes introduced within E2B(R3) are not solely technical, they have a significant impact on the overall pharmacovigilance processes. In this post we look at some of regulatory changes specifically called out by the EMA.

Read more

Over recent years there has been a significant increase in the regulations surrounding the safety of pharmaceutical products. Regardless of size or geolocation, all life science companies are obliged to collect, investigate and monitor adverse events related to their entire portfolio of medicinal products. Over the years, various legislation has defined the process of adverse event reporting, and most recently E2B(R3) introduces the latest iteration to the ICH E2B technical specification.

Read more

The idea is simple - to remain compliant, life sciences organizations need to demonstrate that they are in control of their business, processes and data. Whatever the regulation, the higher the degree of internal data governance, the lower the cost and effort associated with compliance. Non-compliance is not an option and regulators do not hesitate to impose fines costing millions of dollars or withdraw products from the market for failure to do so.

Read more

Copyright ©  2017  EXTEDO. All rights reserved.